Dermata Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.dermatarx.com
- Introduction
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
DMT310-009 Topical in the Treatment of Acne Vulgaris
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Dermata Therapeutics
- Target Recruit Count
- 555
- Registration Number
- NCT06090721
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸DermResearch, Austin, Texas, United States
DMT310-005 Topical in the Treatment of Acne Rosacea
- Conditions
- Acne Rosacea
- Interventions
- Drug: Placebo Topical PowderDrug: Topical Powder
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Dermata Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05108025
- Locations
- 🇺🇸
Dermata Investigational Site, Austin, Texas, United States
DMT310-003 Topical in the Treatment of Acne Vulgaris
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Dermata Therapeutics
- Target Recruit Count
- 181
- Registration Number
- NCT04106778
- Locations
- 🇺🇸
Dermata Investigational Site, Austin, Texas, United States
DMT310-001 Topical in the Treatment of Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Dermata Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT03536637
- Locations
- 🇺🇸
Dermata Investigational Site, Katy, Texas, United States
DMT210 Topical Gel in the Treatment of Acne Rosacea
- Conditions
- Acne Rosacea
- Interventions
- Drug: DMT210 Topical Gel 5%Other: Vehicle Control
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Dermata Therapeutics
- Target Recruit Count
- 107
- Registration Number
- NCT03003104
- Locations
- 🇺🇸
Dermata Investigational Site, Norfolk, Virginia, United States
- Prev
- 1
- 2
- Next
News
Dermata Completes Patient Visits in Pivotal Phase 3 XYNGARI Trial for Moderate-to-Severe Acne
Dermata Therapeutics has completed the last patient visit in its pivotal Phase 3 STAR-1 clinical trial of XYNGARI, a novel once-weekly topical treatment for moderate-to-severe acne, with topline results expected by end of March 2025.
Rosacea Therapeutics Pipeline Shows Promise with Emerging Therapies
Over 25 companies are developing novel rosacea treatments, indicating a robust pipeline.
Dermata's Xyngari Receives FDA Proprietary Name Approval for Acne Treatment
Dermata Therapeutics received FDA approval for the proprietary name Xyngari (formerly DMT310) for its Phase 3 acne treatment candidate.
Dermata Therapeutics' DMT310 Nears Phase III Acne Trial Results
Dermata Therapeutics' DMT310, a novel topical product, is in Phase III trials for moderate-to-severe acne, offering a once-weekly treatment option.
Dermata Therapeutics to Present Phase 3 Acne Program Update at Maxim Healthcare Virtual Summit
Dermata Therapeutics CEO Gerry Proehl will present at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024, at 3:30 PM ET.
Dermata Therapeutics Advances Phase 3 Trial for Novel Once-Weekly Acne Treatment DMT310
Dermata Therapeutics reports steady enrollment progress in its Phase 3 STAR-1 clinical trial for DMT310, a once-weekly topical acne treatment derived from freshwater sponge technology.